Everything below concerns glucose-dependent. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU. It was patented in 1967 and approved for medical use in 1972.
=== Modern method === Deep-frozen stomachs are milled and put into an enzyme-extracting solution. The crude rennet extract is then activated by adding acid; the enzymes in the stomach are produced in an inactive form and are activated by the stomach acid. The acid is then neutralized and the rennet extract is filtered in several stages and concentrated until reaching a typical potency of about 1:15,000; meaning 1 g of extract can coagulate 15 kg of milk. One kilogram of rennet extract has about 0.7 g of active enzymes – the rest is water and salt and sometimes sodium benzoate (E211), 0.5%–1.0% for preservation. Typically, 1 kg of cheese contains about 0.3 mg of rennet enzymes.
Kennedy criticized the hearing, saying, "No fair-minded American can believe that he's not qualified—he went to Yale Law School; he didn't get his law degree from Costco. He has a total command of Supreme Court precedent. I think he’s a legal rock star." Kennedy broke from Republicans during the hearing to call for the FBI's investigation into Ford's allegations to be made public. In March 2018, after a dog died in an overhead bin while flying United Airlines, Kennedy said he would file a bill to "prohibit airlines from putting animals in overhead bins" and added that officials "would face significant fines" if they did not comply. That month, he introduced the Welfare Of Our Furry Friends (WOOFF) Act, but the bill died in committee. In July 2018, Kennedy and several other Republican members of Congress met with Russian government officials in Moscow. During the meetings, the two sides discussed election interference, upholding nuclear arms treaties, maintaining peace in Syria, and respecting Ukrainian sovereignty. The delegation was criticized for visiting the country during Fourth of July celebrations and for holding the talks just days after an incident in the United Kingdom in which a couple were poisoned by a suspected Russian nerve agent. On October 12, 2018, the Senate voted to pass Kennedy's Rural Business Investment Program Advisers Relief Act of 2018. The bill removes compliance costs on a venture capital program aimed at stimulating business in rural America. It became law in 2019.
Technology & commerce: Home to the Rajiv Gandhi IT Park, which houses campuses for Infosys, Tech Mahindra, and Airtel. It also features Asia's largest motor market and major shopping centers like Fun Republic and DT Mall. Residential & facilities: The area contains a mix of urban societies (Uppal's Marble Arch, Rajeev Vihar) and traditional localities (Mari Wala Town, Pipliwala Town). It is supported by the Kalagram cultural center, The Lalit 5-star hotel, and several prominent schools including RIMT World School and Gurukul Global.
Sources: en.wikipedia.org
== Life and work == Bergmann was born in Fürth, Bavaria, Germany on February 12, 1886, the seventh child of coal wholesalers Salomon and Rosalie Bergmann. Bergmann started studying biology at the Ludwig-Maximilians-Universität München, but lectures by Adolf von Baeyer captured his interest and eventually persuaded him to switch to Organic Chemistry. He continued his chemical studies at the Friedrich Wilhelm University of Berlin, where he was taught by Emil Fischer. After receiving his PhD under the supervision of Ignaz Bloch [de] in 1911 for his thesis on acyl(polysulfides), he became the assistant to Fischer at the University of Berlin, where he stayed until Fischer's death in 1919. He received his habilitation in 1921. In 1922 Bergmann was made the first director of the Kaiser Wilhelm Institute for Leather Research in Dresden, which was created in 1921 and from which the Max Planck Institute of Biochemistry descends. It was there that he worked with his former doctoral student, Leonidas Zervas, who eventually rose to vice-director of the institute and briefly succeeded Bergmann as director. In the early 1930s, the two scientists developed the Bergmann-Zervas carbobenzoxy method for the synthesis of polypeptides, which started the field of controlled peptide chemical synthesis and remained the dominant method in it for the next 20 years. Bergmann and Zervas gained international academic fame as a result. Bergmann was nonetheless forced to abandon his institute due to his Jewish origin after the passage of the Civil Service Law and emigrated from Nazi Germany in 1933.
Graft copolymers are a special type of branched copolymer wherein the side chains are structurally distinct from the main chain. Typically, the main chain is formed from one type of monomer (A) and branches are formed from another monomer (B), or the side-chains have constitutional or configurational features that differ from those in the main chain. The individual chains of a graft copolymer may be homopolymers or copolymers. Note that different copolymer sequencing is sufficient to define a structural difference, thus an A-B diblock copolymer with A-B alternating copolymer side chains is properly called a graft copolymer. For example, polystyrene chains may be grafted onto polybutadiene, a synthetic rubber which retains one reactive C=C double bond per repeat unit. The polybutadiene is dissolved in styrene, which is then subjected to free-radical polymerization. The growing chains can add across the double bonds of rubber molecules forming polystyrene branches. The graft copolymer is formed in a mixture with ungrafted polystyrene chains and rubber molecules. As with block copolymers, the quasi-composite product has properties of both "components." In the example cited, the rubbery chains absorb energy when the substance is hit, so it is much less brittle than ordinary polystyrene. The product is called high-impact polystyrene, or HIPS.
=== Pharmacokinetics === Bromantane is used clinically in doses of 50 mg to 100 mg per day in the treatment of asthenia. The rate of absorption in women is greater than in men, with maximum blood concentrations being reached at 2.75 and 4 hours after oral administration, respectively. The main metabolite of bromantane is 6β-hydroxybromantane.
Sources: en.wikipedia.org
=== Insulin glargine === Insulin glargine is a long-acting modified form of medical insulin used in the management of type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects typically begin within an hour of injection. Common side effects include (hypoglycemia, issues at the injection site, itchiness, and weight gain. NPH insulin is generally preferred over insulin glargine during pregnancy. After injection, microcrystals gradually release insulin over a period of approximately 24 hours. This insulin works by facilitating the absorption of glucose by body tissues and reducing glucose production by the liver. Insulin glargine was patented, although the patent expired in most countries in 2014. It was approved for medical use in the United States in 2000. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it ranked as the 28th most commonly prescribed medication in the United States, with more than 18 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), for the treatment of diabetes. Unbranded versions of insulin glargine and insulin glargine-yfgn are sold by Sanofi and Viatris.
== External links == "Do insects have blood?". Boston Globe. October 17, 2005. Archived from the original on October 2, 2022. Bolstad, Kat (May 2, 2008). "Blue Squid Blood - Murky Water". Te Papa Tongarewa Museum of New Zealand. Archived from the original on April 2, 2015.
This is an example of the Nernst equation. The potential is known as a reduction potential. Standard electrode potentials are available in a table of values. Using these values, the actual electrode potential for a redox couple can be calculated as a function of the ratio of concentrations. The equilibrium potential for a general redox half-reaction (See #Equilibrium constant above for an explanation of the symbols)
=== Live insect feed === Other insects not killed by farming companies are sold live for consumption by fish and pets. 95% of the Kreca company's insects are sold live. Of the 1500 kg per week of mealworms produced by the Van de Ven company, most are sold as live feed. Live insects may be required for some pets that will not consume dead prey. For instance, monitor lizards are typically fed live insects and may not eat pre-killed ones. It is generally hard to convert reptiles and amphibians that eat insects to pre-killed prey, though some pet owners can feed dead insects by moving or dangling them. For instance, bearded dragons can be fed dead crickets by hiding them in other food, dangling them with tongs, squirting them with water, or vibrating a bowl. Pet spiders, or praying mantids and other insectivorous bugs, typically require live food. Live insects may also be commonly used as fishing bait, with the result that they are either eaten alive by fish or drowned.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.